Yeong Sang Kim

Phase II Trial of Bevacizumab, Thalidomide, Docetaxel, and Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer

Yang‐Min Ning, James L. Gulley, Philip M. Arlen et al. · Journal of Clinical Oncology · 2010 · 145 citations · Full text

Medicine, Oncology, Pharmacology +17

A Phase I Study of PF-04929113 (SNX-5422), an Orally Bioavailable Heat Shock Protein 90 Inhibitor, in Patients with Refractory Solid Tumor Malignancies and Lymphomas

Arun Rajan, Ronan J. Kelly, Jane B. Trepel et al. · Clinical Cancer Research · 2011 · 142 citations · Full text

Medicine, Oncology, Pharmacology +16

Targeting the regulation of androgen receptor signaling by the heat shock protein 90 cochaperone FKBP52 in prostate cancer cells

Johanny Tonos De Leon, Aki Iwai, Clémentine Féau et al. · Proceedings of the National Academy of Sciences · 2011 · 134 citations

Life Sciences, Oncology, Pharmacology +17

Targeting the Hsp40/Hsp70 Chaperone Axis as a Novel Strategy to Treat Castration-Resistant Prostate Cancer

Michael A. Moses, Yeong Sang Kim, Génesis M. Rivera-Márquez et al. · Cancer Research · 2018 · 125 citations

Medicine, Oncology, Pharmacology +17

An Electrophoretic Mobility Shift Assay Identifies a Mechanistically Unique Inhibitor of Protein Sumoylation

Yeong Sang Kim, Katelyn J. Nagy, Samantha G. L. Keyser et al. · Chemistry & Biology · 2013 · 90 citations

Life Sciences, Biochemistry, Molecular Biology +6